SCHEMBL15081978

SCHEMBL15081978

CC(C)C1CCCN(Cc2ccnc3ccccc23)C1

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.50
KDM4E B2RXH2 1/20 0.50
LMNA P02545 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50
MAPK1 P28482 1/20 0.47
HSD11B1 P28845 1/20 0.45
MEN1 O00255 3/20 0.45
KMT2A Q03164 3/20 0.45
TSHR P16473 1/20 0.43
FAAH O00519 1/20 0.43
OPRM1 P35372 2/20 0.42
HRH3 Q9Y5N1 3/20 0.41
OPRK1 P41145 1/20 0.40
OPRL1 P41146 1/20 0.40
BRD4 O60885 1/20 0.39
CYP2D6 P10635 2/20 0.39
LOXL2 Q9Y4K0 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15081995 0.92 ALDH1A1 (0.56) ALDH1A1KDM4ELMNASMN1; SMN2NPSR1
SCHEMBL15084315 0.84 ALDH1A1 (0.53) ALDH1A1KDM4ELMNASMN1; SMN2NPSR1
SCHEMBL15081975 0.81 TSHR (0.66) ALDH1A1KDM4ESMN1; SMN2MEN1KMT2A
SCHEMBL15081977 0.81 TSHR (0.46) ALDH1A1KDM4ESMN1; SMN2NPSR1MAPK1
SCHEMBL807183 0.81 TSHR (0.66) ALDH1A1KDM4ESMN1; SMN2MEN1KMT2A
SCHEMBL23507365 0.78 KDM4E (0.70) ALDH1A1KDM4ELMNASMN1; SMN2NPSR1
SCHEMBL23507385 0.78 LMNA (0.56) ALDH1A1KDM4ELMNASMN1; SMN2NPSR1
SCHEMBL19844839 0.77 LMNA (0.51) ALDH1A1KDM4ELMNASMN1; SMN2KMT2A
SCHEMBL807235 0.77 KDM4E (0.68) ALDH1A1KDM4ELMNASMN1; SMN2NPSR1
SCHEMBL31010255 0.77 KDM4E (0.68) ALDH1A1KDM4ELMNASMN1; SMN2NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9242981-B2 Fused pyrazole derivatives as novel ERK inhibitors MERCK SHARP & DOHME CORP. (US) 2016-01-26 US disclosed
US-20130172341-A1 FUSED PYRAZOLE DERIVATIVES AS NOVEL ERK INHIBITORS MERCK SHARP & DOHME LLC 2013-07-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130172341-A1 FUSED PYRAZOLE DERIVATIVES AS NOVEL ERK INHIBITORS MAPK1, MAPK3, MAP3K1 ALDH1A1 781/4885KDM4E 3317/4885LMNA 4751/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.